PJ3-047 Site Specific Effects of Quinidine on Repolarization Abnormalities in Patiens with Brugada Type ECG by Using Body Surface Mapping System

Research output: Contribution to journalArticle

Abstract

Brugada syndrome (BS) is characterized by ST-elevation in leads V1-3, and coexistence of the early repolarization in the left-lateral or inferior leads has been reported as a predictor of VF episodes. Quinidine is a candidate of terapeutic drugs and decreases ST level in some patients. We evaluate the effects of quinidine on ST elevation in three ventricular sites (RVOT, Inferior part and LV) by using body surface mapping system (BSM).We enroled 36 patients with BS-type ECG (asymptomatic 22 pts, VF 11 pts). We recorded ECGs and BSM before and after administration of quinidine (200mg,p. o.) and measured the ECG parameters and the voltage of the ST segment 20ms after J point (ST 20) by the BSM. There were no differences in RR,PQ, and QRS intervals before and after quinidine administration. ST elevation (V2) was attenuated after quinidine treatment (before: 0.28± 0.14mV,v. s. after: 0.23 ± 0.13mV, p=0.03). BSM: ST20 was the highest in the RVOT before quinidine treatment. Quinidine attenuated the ST elevation in the RVOT in VF group (before: 0.23±0.16 mV, v.s. after: 0.16±0.12 mV, p<0.01) and asymptomatic group (before: 0.20±0.13 mV,v.s. after: 0.18± 0.12 mV, p<0.01) but not in other areas. Quinidine improved repolarization abnormality in the RVOT specifically, but not in other areas. The mechanism of the ST elevation in LV and INF might be different from the RVOT.

Original languageEnglish
JournalJournal of Arrhythmia
Volume27
DOIs
Publication statusPublished - 2011

Fingerprint

Body Surface Potential Mapping
Quinidine
Electrocardiography
Brugada Syndrome

Keywords

  • body surface mapping
  • Brugada syndrome
  • quinidine administration

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{7a8f88e5dba247b980fc182e54bc4a82,
title = "PJ3-047 Site Specific Effects of Quinidine on Repolarization Abnormalities in Patiens with Brugada Type ECG by Using Body Surface Mapping System",
abstract = "Brugada syndrome (BS) is characterized by ST-elevation in leads V1-3, and coexistence of the early repolarization in the left-lateral or inferior leads has been reported as a predictor of VF episodes. Quinidine is a candidate of terapeutic drugs and decreases ST level in some patients. We evaluate the effects of quinidine on ST elevation in three ventricular sites (RVOT, Inferior part and LV) by using body surface mapping system (BSM).We enroled 36 patients with BS-type ECG (asymptomatic 22 pts, VF 11 pts). We recorded ECGs and BSM before and after administration of quinidine (200mg,p. o.) and measured the ECG parameters and the voltage of the ST segment 20ms after J point (ST 20) by the BSM. There were no differences in RR,PQ, and QRS intervals before and after quinidine administration. ST elevation (V2) was attenuated after quinidine treatment (before: 0.28± 0.14mV,v. s. after: 0.23 ± 0.13mV, p=0.03). BSM: ST20 was the highest in the RVOT before quinidine treatment. Quinidine attenuated the ST elevation in the RVOT in VF group (before: 0.23±0.16 mV, v.s. after: 0.16±0.12 mV, p<0.01) and asymptomatic group (before: 0.20±0.13 mV,v.s. after: 0.18± 0.12 mV, p<0.01) but not in other areas. Quinidine improved repolarization abnormality in the RVOT specifically, but not in other areas. The mechanism of the ST elevation in LV and INF might be different from the RVOT.",
keywords = "body surface mapping, Brugada syndrome, quinidine administration",
author = "Makiko Taniyama and Hiroshi Morita",
year = "2011",
doi = "10.4020/jhrs.27.PJ3_047",
language = "English",
volume = "27",
journal = "Journal of Arrhythmia",
issn = "1880-4276",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - PJ3-047 Site Specific Effects of Quinidine on Repolarization Abnormalities in Patiens with Brugada Type ECG by Using Body Surface Mapping System

AU - Taniyama, Makiko

AU - Morita, Hiroshi

PY - 2011

Y1 - 2011

N2 - Brugada syndrome (BS) is characterized by ST-elevation in leads V1-3, and coexistence of the early repolarization in the left-lateral or inferior leads has been reported as a predictor of VF episodes. Quinidine is a candidate of terapeutic drugs and decreases ST level in some patients. We evaluate the effects of quinidine on ST elevation in three ventricular sites (RVOT, Inferior part and LV) by using body surface mapping system (BSM).We enroled 36 patients with BS-type ECG (asymptomatic 22 pts, VF 11 pts). We recorded ECGs and BSM before and after administration of quinidine (200mg,p. o.) and measured the ECG parameters and the voltage of the ST segment 20ms after J point (ST 20) by the BSM. There were no differences in RR,PQ, and QRS intervals before and after quinidine administration. ST elevation (V2) was attenuated after quinidine treatment (before: 0.28± 0.14mV,v. s. after: 0.23 ± 0.13mV, p=0.03). BSM: ST20 was the highest in the RVOT before quinidine treatment. Quinidine attenuated the ST elevation in the RVOT in VF group (before: 0.23±0.16 mV, v.s. after: 0.16±0.12 mV, p<0.01) and asymptomatic group (before: 0.20±0.13 mV,v.s. after: 0.18± 0.12 mV, p<0.01) but not in other areas. Quinidine improved repolarization abnormality in the RVOT specifically, but not in other areas. The mechanism of the ST elevation in LV and INF might be different from the RVOT.

AB - Brugada syndrome (BS) is characterized by ST-elevation in leads V1-3, and coexistence of the early repolarization in the left-lateral or inferior leads has been reported as a predictor of VF episodes. Quinidine is a candidate of terapeutic drugs and decreases ST level in some patients. We evaluate the effects of quinidine on ST elevation in three ventricular sites (RVOT, Inferior part and LV) by using body surface mapping system (BSM).We enroled 36 patients with BS-type ECG (asymptomatic 22 pts, VF 11 pts). We recorded ECGs and BSM before and after administration of quinidine (200mg,p. o.) and measured the ECG parameters and the voltage of the ST segment 20ms after J point (ST 20) by the BSM. There were no differences in RR,PQ, and QRS intervals before and after quinidine administration. ST elevation (V2) was attenuated after quinidine treatment (before: 0.28± 0.14mV,v. s. after: 0.23 ± 0.13mV, p=0.03). BSM: ST20 was the highest in the RVOT before quinidine treatment. Quinidine attenuated the ST elevation in the RVOT in VF group (before: 0.23±0.16 mV, v.s. after: 0.16±0.12 mV, p<0.01) and asymptomatic group (before: 0.20±0.13 mV,v.s. after: 0.18± 0.12 mV, p<0.01) but not in other areas. Quinidine improved repolarization abnormality in the RVOT specifically, but not in other areas. The mechanism of the ST elevation in LV and INF might be different from the RVOT.

KW - body surface mapping

KW - Brugada syndrome

KW - quinidine administration

UR - http://www.scopus.com/inward/record.url?scp=85008722288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008722288&partnerID=8YFLogxK

U2 - 10.4020/jhrs.27.PJ3_047

DO - 10.4020/jhrs.27.PJ3_047

M3 - Article

VL - 27

JO - Journal of Arrhythmia

JF - Journal of Arrhythmia

SN - 1880-4276

ER -